Mara Glickman Aspinall's most recent trade in Orasure Technologies Inc. was a trade of 71,017 Common Stock done . Disclosure was reported to the exchange on May 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 71,017 | 178,758 (0%) | 0% | 0 | Common Stock | |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.65 per share. | 13 May 2025 | 6,666 | 107,741 (0%) | 0% | 2.7 | 17,682 | Common Stock |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 8,636 | 0 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 8,636 | 44,139 (0%) | 0% | - | Common Stock | |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 24,691 | 114,407 (0%) | 0% | 0 | Common Stock | |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.26 per share. | 14 May 2024 | 6,619 | 89,716 (0%) | 0% | 5.3 | 34,849 | Common Stock |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 02 Jun 2023 | 3,825 | 35,503 (0%) | 0% | - | Common Stock | ||
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 02 Jun 2023 | 3,825 | 0 | - | - | Restricted Stock Units | ||
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 25 May 2023 | 8,636 | 8,636 | - | - | Restricted Stock Units | ||
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 24,517 | 96,335 (0%) | 0% | 0 | Common Stock | |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.62 per share. | 15 May 2023 | 5,400 | 71,818 (0%) | 0% | 5.6 | 30,321 | Common Stock |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Purchase of securities on an exchange or from another person at price $ 4.19 per share. | 25 Aug 2022 | 6,000 | 77,218 (0%) | 0% | 4.2 | 25,138 | Common Stock |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 10 Jun 2022 | 830 | 31,678 (0%) | 0% | 0 | Common Stock | ||
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 10 Jun 2022 | 830 | 0 | - | - | Restricted Stock Units | ||
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Grant, award, or other acquisition of securities at price $ 4.00 per share. | 03 Jun 2022 | 24,983 | 77,963 (0%) | 0% | 4.0 | 99,999 | Common Stock |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.00 per share. | 03 Jun 2022 | 6,745 | 71,218 (0%) | 0% | 4.0 | 26,998 | Common Stock |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 02 Jun 2022 | 7,647 | 7,647 | - | - | Stock option (right to buy) | ||
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 02 Jun 2022 | 3,825 | 3,825 | - | - | Restricted Stock Units | ||
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Grant, award, or other acquisition of securities at price $ 5.25 per share. | 16 May 2022 | 20,000 | 52,980 (0%) | 0% | 5.3 | 105,000 | Common Stock |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.25 per share. | 16 May 2022 | 2,957 | 32,980 (0%) | 0% | 5.2 | 15,524 | Common Stock |
| Veradigm Inc | Mara Glickman Aspinall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 12,056 | 95,943 (0%) | 0% | 0 | Common Stock | |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Grant, award, or other acquisition of securities at price $ 9.59 per share. | 17 May 2021 | 10,952 | 35,937 (0%) | 0% | 9.6 | 105,002 | Common Stock |
| Orasure Technologies Inc. | Mara Glickman Aspinall | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.50 per share. | 17 May 2021 | 1,775 | 24,985 (0%) | 0% | 9.5 | 16,865 | Common Stock |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 02 Oct 2020 | 2,500 | 30,848 (0%) | 0% | 52.5 | 131,200 | Common Stock | |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 09 Sep 2020 | 2,500 | 33,348 (0%) | 0% | 50.5 | 126,200 | Common Stock | |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 04 Sep 2020 | 2,500 | 35,848 (0%) | 0% | 48.5 | 121,200 | Common Stock | |
| Castle Biosciences Inc | Mara Glickman Aspinall | Director | 28 Aug 2020 | 2,500 | 38,348 (0%) | 0% | 46.5 | 116,200 | Common Stock |